文献速递瓣膜病与结构性心脏病冠心病

急性心肌梗死后二尖瓣反流的保守、外科与经导管治疗比较

Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction.
PubMed 文献 · Eur Heart J · 2022-01-01

该国际注册研究纳入471例急性心梗后至少中重度二尖瓣反流患者,比较保守治疗与外科或经导管二尖瓣干预的结局。干预组虽临床状态更差,但院内和1年死亡率低于保守组;经导管修复的院内和1年死亡率低于外科手术。

要点

  • 心梗后二尖瓣反流患者早期干预可能改善预后
  • 经导管二尖瓣修复可作为高危患者的外科替代选择
  • 外科手术的院内和1年死亡率高于经导管修复

核心结论

  • 早期干预可能减轻心梗后二尖瓣反流患者保守治疗相关的不良预后。
  • 经导管二尖瓣修复可作为高危患者减少二尖瓣反流的外科替代选择。

研究设计与样本

  • 回顾性国际注册研究,连续纳入北美、欧洲和中东21个中心的急性心梗后至少中重度二尖瓣反流患者。
  • 共纳入471例患者(43%女性,年龄73±11岁),其中205例接受干预(106例外科二尖瓣修复或置换,99例经导管二尖瓣修复),其余接受保守治疗。

主要发现

  • 接受二尖瓣干预的患者临床状态更差(Killip≥3级60% vs 43%,P<0.01),但院内和1年死亡率低于保守治疗组(11% vs 27%,P<0.01;16% vs 35%,P<0.01;校正HR 0.28,95%CI 0.18-0.46,P<0.01)。
  • 外科二尖瓣修复或置换较经导管二尖瓣修复更早进行(自心梗日期中位数12天(IQR 5-19)vs 19天(10-40),P<0.01)。
  • 外科与经导管修复的即刻手术成功率无差异(92% vs 93%,P=0.53),但外科组院内和1年死亡率显著高于经导管组(16% vs 6%,P=0.03;31% vs 17%,P=0.04;校正HR 3.75,95%CI 1.55-9.07,P<0.01)。

临床怎么用

  • 对于急性心梗后至少中重度二尖瓣反流患者,应考虑早期干预而非仅保守治疗。
  • 高危患者可优先考虑经导管二尖瓣修复作为外科手术的替代方案。

局限性

  • 回顾性注册研究设计,存在选择偏倚可能。
  • 干预组与保守组临床状态基线不同,尽管进行了校正,仍可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Severe mitral regurgitation (MR) following acute myocardial infarction (MI) is associated with high mortality rates and has inconclusive recommendations in clinical guidelines. We aimed to report the international experience of patients with secondary MR following acute MI and compare the outcomes of those treated conservatively, surgically, and percutaneously. METHODS AND RESULTS: Retrospective international registry of consecutive patients with at least moderate-to-severe MR following MI treated in 21 centres in North America, Europe, and the Middle East. The registry included patients treated conservatively and those having surgical mitral valve repair or replacement (SMVR) or percutaneous mitral valve repair (PMVR) using edge-to-edge repair. The primary endpoint was in-hospital mortality. A total of 471 patients were included (43% female, age 73 ± 11 years): 205 underwent interventions, of whom 106 were SMVR and 99 PMVR. Patients who underwent mitral valve intervention were in a worse clinical state (Killip class ≥3 in 60% vs. 43%, P < 0.01), but yet had lower in-hospital and 1-year mortality compared with those treated conservatively [11% vs. 27%, P < 0.01 and 16% vs. 35%, P < 0.01; adjusted hazard ratio (HR) 0.28, 95% confidence interval (CI) 0.18-0.46, P < 0.01]. Surgical mitral valve repair or replacement was performed earlier than PMVR [median of 12 days from MI date (interquartile range 5-19) vs. 19 days (10-40), P < 0.01]. The immediate procedural success did not differ between SMVR and PMVR (92% vs. 93%, P = 0.53). However, in-hospital and 1-year mortality rates were significantly higher in SMVR than in PMVR (16% vs. 6%, P = 0.03 and 31% vs. 17%, P = 0.04; adjusted HR 3.75, 95% CI 1.55-9.07, P < 0.01). CONCLUSIONS: Early intervention may mitigate the poor prognosis associated with conservative therapy in patients with post-MI MR. Percutaneous mitral valve repair can serve as an alternative for surgery in reducing MR for high-risk patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Haberman D, Estévez-Loureiro R, Benito-Gonzalez T, et al. Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. Eur Heart J. 2022. PMID: 34463727. doi:10.1093/eurheartj/ehab496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。